CareDx Q1 2026 Earnings: COO Keith Kennedy Highlights 39% Revenue Rise and $170 M Lab Divestiture

Why It Matters

The CareDx earnings release marks a decisive pivot from low‑margin lab products to high‑margin, data‑driven testing services and digital solutions. By shedding a $10 million revenue line for a $170 million cash infusion, the company strengthens its balance sheet and reallocates capital toward growth engines that align with a $12 billion total addressable market in transplant and oncology diagnostics. For COOs across biotech, the results illustrate how operational restructuring—divestitures, strategic acquisitions, and technology integration—can unlock margin expansion while preserving cash flow. Moreover, the emphasis on Epic integration and digital adoption signals a broader industry trend: diagnostic firms are moving beyond pure assay execution to become platform providers embedded in clinical workflows. This shift raises the stakes for operational leaders to manage complex IT projects, physician onboarding, and data‑analytics pipelines while maintaining stringent regulatory compliance. CareDx’s ability to deliver a 10% increase in revenue per test without sacrificing gross margin will be a benchmark for peers evaluating similar digital‑first strategies.

Key Takeaways

• Q1 revenue $118 M, up 39% YoY
• Testing‑services revenue $91 M, up 48%
• Lab‑products divestiture signed for $170 M upfront cash
• Adjusted EBITDA $19 M, >300% YoY growth
• Full‑year revenue guidance raised to $447‑$465 M

Pulse Analysis

CareDx’s Q1 performance underscores a classic COO playbook: prune underperforming assets, double‑down on high‑margin services, and leverage technology to scale. The $170 million lab‑products divestiture not only removes a segment with flat growth but also injects cash that can be deployed without diluting shareholders—a move that should appease both growth‑oriented investors and those focused on balance‑sheet strength. The Navaris acquisition, while modest in size, adds a sizable test volume base and a physician network that can accelerate cross‑selling of CareDx’s digital transplant solutions.

From an operational standpoint, the company’s push to route half of its testing volume through Epic by year‑end is ambitious. Epic integration typically involves complex change‑management, data‑mapping, and compliance hurdles. Success will hinge on the COO’s ability to synchronize IT, lab operations, and clinical teams—a challenge that, if met, could set a new efficiency benchmark in the diagnostics space. The projected 10% uplift in revenue per test, driven partly by improved accrual rates and cash‑collection efficiencies, suggests that CareDx is extracting more value from each assay without a proportional cost increase.

Looking forward, the real test will be whether the combined effect of the Navaris acquisition, Epic integration, and the newly freed capital can sustain the 13% annual testing‑volume growth and deliver the mid‑point adjusted EBITDA target of $50 M for 2026. If CareDx can meet these milestones, it will validate a COO‑centric growth model that other biotech firms may emulate, especially those wrestling with legacy lab assets and the need to transition toward data‑centric service offerings.